Advancing cardiovascular research requires tools that can precisely target the heart's complex cell types. OBiO offers a comprehensive suite of AAV vector solutions to support your breakthrough discoveries.

Our core product line includes:

· Targeting Cardiomyocytes: AAV Heart system or AAV9 + cTnT promoter;

· Targeting Cardiac Fibroblasts: AAV9 + TC21 promoter;

· Targeting Cardiac Myofibroblasts: AAV9 + Postn promoter;

· Targeting Vascular Smooth Muscle Cells (VSMCs): AAV9 + SM22α promoter;

· Targeting Vascular Endothelial Cells: AAV9 + hFLT1/Tie1 Promoter or AAV-Vec Serotype;

· Vector for Modeling Cardiometabolic Diseases like Hypercholesterolemia, Atherosclerosis, and Vascular calcification: AAV-PCSK9.

References:

[1] Circ Res. 2020 Apr 10;126(8):1024-1039. doi: 10.1161/CIRCRESAHA.119.315956.

[2] Gene Ther. 2011 Jan;18(1):43-52. doi: 10.1038/gt.2010.105.

[3] Mol Ther. 2011 Sep;19(9):1582-90. doi: 10.1038/mt.2011.124.

[4] Hum Gene Ther. 2019 Oct;30(10):1284-1296. doi: 10.1089/hum.2019.027.

[5] Clin Sci (Lond). 2021 Jun 11;135(11):1369-1387. doi: 10.1042/CS20210052.

[6] NPJ Biofilms Microbiomes. 2025 May 23;11(1):86. doi: 10.1038/s41522-025-00712-y.

[7] Cell Commun Signal. 2024 Sep 20;22(1):444. doi: 10.1186/s12964-024-01826-0.

[8] Br J Pharmacol. 2023 Sep;180(17):2266-2279. doi: 10.1111/bph.16082.